Table 1.

Baseline characteristics of RA, PsA and AS patients

CharacteristicsTotal cohort N=127RA N=41PsA N=52AS N=34
Female gender (%)75 (60)35 (85)31 (59)9 (26)
Age (years)61.7±12.7860.5±12.6461.55±11.656.3±10.71
Disease duration (years)15.86±9.4917.23±10.6413.75±6.5714.92±9.50
Comorbidities, (%)17,8 (14)5,7 (14)9,8 (19)2 (6)
ACPA+, n (%)-25 (63.3)--
RF+, n (%)24 (62.5)
HLAB27+, n (%)--8 (15)17 (50)
CRP (mg/L)1.65±2.272.31±1.900.42±0.271.36±1.91
DAS 28-2.65±0.75
DAPSA-8.25±3.69
BASDAI-3.23±1.58
HAQ0.73±0.570.72±0.550.73±0.520.76±0.69
Prednisone, n (%)46 (36)23 (55)20 (44)3 (13)
Combo Therapy65 (51)29 (68)25 (48)11 (32)
oADA duration (months)49.74±40.7556.43±41.2725.00±13.6740.08±37.78
ABP501 duration (months)12.42±2.4112.77±2.3412.82±1.4912.49±2.95
SB501 duration (months)11.92±1.4112.47±1.7412.72±1.4912.41±1.95
  • ABP501 (Adalimumab biosimilar, Amgevita), SB501 (Adalimumab biosimilar, Imraldi)